The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 15, 2013
Filed:
Sep. 22, 2009
Arnab Chakravarti, Dublin, OH (US);
Robert Pinard, Andover, MA (US);
Agnes Ang, Newbury Park, CA (US);
Marisa P. Dolled-filhart, New Haven, CT (US);
Annette Molinaro, New Haven, CT (US);
Alpana Waldron, Fairfield, CT (US);
Arnab Chakravarti, Dublin, OH (US);
Robert Pinard, Andover, MA (US);
Donald Waldron, Fairfield, CT (US);
Agnes Ang, Newbury Park, CA (US);
Marisa P. Dolled-Filhart, New Haven, CT (US);
Annette Molinaro, New Haven, CT (US);
HistoRx, Inc., New Haven, CT (US);
Radiation Therapy Oncology Group of the American College of Radiology, Philadelphia, PA (US);
Abstract
Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.